Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

समान संसाधन

• Effect of concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) on the efficacy and safety of ixekizumab in biologic dmard-naive patients with active psoriatic arthritis
  द्वारा: Coates, LC, और अन्य
  प्रकाशित: (2016)
• Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
  द्वारा: Juthamas Prawjaeng, और अन्य
  प्रकाशित: (2023-05-01)
• HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
  द्वारा: Antonio Gasbarrini, और अन्य
  प्रकाशित: (2020-02-01)
• Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
  द्वारा: Giacomo Cozzi, और अन्य
  प्रकाशित: (2024-12-01)
• The efficacy of tofacitinib combined with bDMARDs in the treatment of ankylosing spondylitis patients with inadequate response to bDMARDs: a retrospective study
  द्वारा: Jie Chang, और अन्य
  प्रकाशित: (2024-01-01)